Meeting
2013 Genitourinary Cancers Symposium
Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib.
Authors
Robert John Motzer
Memorial Sloan-Kettering Cancer Center, New York, NY
Robert John Motzer , Dmitry Nosov , Piotr Tomczak , Anna Berkenblit , Brooke Esteves , Andrew Louis Strahs , Thomas E. Hutson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT01076010
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 364)
DOI
10.1200/jco.2013.31.6_suppl.364
Abstract #
364
Poster Bd #
C1
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902).
First Author: Thomas Hutson
Poster
2024 ASCO Genitourinary Cancers Symposium
Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC).
First Author: Andrew Johns
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Evaluating the safety and efficacy of the addition of liver radiation (RT) to atezolizumab and bevacizumab (A/B) in advanced hepatocellular carcinoma (HCC): A retrospective cohort analysis.
First Author: Timothy J. Brown
Poster
2022 ASCO Genitourinary Cancers Symposium
Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.
First Author: Sun Young Rha